Literature DB >> 27696334

Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Shi-Yang Guan1,2, Rui-Xue Leng1,2, Muhammad Imran Khan1,2, Humera Qureshi1,2, Xiang-Pei Li3, Dong-Qing Ye1,2, Hai-Feng Pan4,5.   

Abstract

Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.

Entities:  

Keywords:  Th17 cells; Treg cells; autoimmune diseases; interleukin-35; therapeutic agent

Mesh：

Substances：

Year:  2017        PMID： 27696334     DOI： 10.1007/s10753-016-0453-9

Source DB:  PubMed          Journal:  Inflammation        ISSN： 0360-3997            Impact factor:   4.092


  69 in total

1.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells.

Authors:  Ida Rasmusson; Olle Ringdén; Berit Sundberg; Katarina Le Blanc
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

3.  The composition and signaling of the IL-35 receptor are unconventional.

Authors:  Lauren W Collison; Greg M Delgoffe; Clifford S Guy; Kate M Vignali; Vandana Chaturvedi; DeLisa Fairweather; Abhay R Satoskar; K Christopher Garcia; Christopher A Hunter; Charles G Drake; Peter J Murray; Dario A A Vignali
Journal:  Nat Immunol       Date:  2012-02-05       Impact factor: 25.606

4.  Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia.

Authors:  Liyu Zhou; Feng Xu; Chunkang Chang; Ying Tao; Luxi Song; Xiao Li
Journal:  Blood Coagul Fibrinolysis       Date:  2016-04       Impact factor: 1.276

5.  Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; Kathryn Holderness; Massimo Maddaloni; David W Pascual
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

6.  IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease.

Authors:  Gregory S Whitehead; Rhonda H Wilson; Keiko Nakano; Lauranell H Burch; Hideki Nakano; Donald N Cook
Journal:  J Allergy Clin Immunol       Date:  2011-09-08       Impact factor: 10.793

Review 7.  IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia.

Authors:  Caterina Toriani-Terenzi; Enzo Fagiolo
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

8.  IL-35-mediated induction of a potent regulatory T cell population.

Authors:  Lauren W Collison; Vandana Chaturvedi; Abigail L Henderson; Paul R Giacomin; Cliff Guy; Jaishree Bankoti; David Finkelstein; Karen Forbes; Creg J Workman; Scott A Brown; Jerold E Rehg; Michael L Jones; Hsiao-Tzu Ni; David Artis; Mary Jo Turk; Dario A A Vignali
Journal:  Nat Immunol       Date:  2010-10-17       Impact factor: 25.606

9.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

Review 10.  IL-10-producing regulatory B cells (B10 cells) in autoimmune disease.

Authors:  Ioannis Kalampokis; Ayumi Yoshizaki; Thomas F Tedder
Journal:  Arthritis Res Ther       Date:  2013-02-11       Impact factor: 5.156
View more
  17 in total

1.  Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.

Authors:  Jie Tang; Ling Lei; Jie Pan; Cheng Zhao; Jing Wen
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

2.  IL-35 Pretreatment Alleviates Lipopolysaccharide-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB Activation.

Authors:  Linkun Hu; Cheng Chen; Jun Zhang; Kerong Wu; Xuefeng Zhang; Haiyan Liu; Jianquan Hou
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

3.  IL-35 may maintain homeostasis of the immune microenvironment in periodontitis.

Authors:  Ying Jin; Dixin Liu; Xiaoping Lin
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

Review 4.  Emerging role of semaphorin-3A in autoimmune diseases.

Authors:  Li-Na Liu; Xiao-Mei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammopharmacology       Date:  2018-04-25       Impact factor: 4.473

5.  Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.

Authors:  X Liu; H Ren; H Guo; W Wang; N Zhao
Journal:  Clin Exp Immunol       Date:  2020-10-26       Impact factor: 4.330

Review 6.  Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis.

Authors:  Pan Lin Xin; Li Fan Jie; Qian Cheng; Du Yi Bin; Cheng Wen Dan
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

7.  Interleukin-35 mitigates the function of murine transplanted islet cells via regulation of Treg/Th17 ratio.

Authors:  Yin Zongyi; Zou Funian; Li Hao; Wang Xin; Cheng Ying; Zhang Jialin; Liu Yongfeng; Li Baifeng
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

8.  Lower level of IL‑35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test‑positive hemocytopenia.

Authors:  Yi Li; Yihao Wang; Hui Liu; Kai Ding; Shanfeng Hao; Yuanyuan Shao; Honglei Wang; Jin Chen; Lei Huang; Zonghong Shao; Rong Fu
Journal:  Mol Med Rep       Date:  2017-12-11       Impact factor: 2.952

Review 9.  Stem cell therapies for autoimmune hepatitis.

Authors:  Ahmed Lotfy; Aya Elgamal; Anna Burdzinska; Ayman A Swelum; Reham Soliman; Ayman A Hassan; Gamal Shiha
Journal:  Stem Cell Res Ther       Date:  2021-07-07       Impact factor: 6.832

10.  IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.

Authors:  Yuan Wang; Ying Mao; Junfeng Zhang; Gang Shi; Lin Cheng; Yi Lin; Yiming Li; Xiaomei Zhang; Yujing Zhang; Xiaolei Chen; Jie Deng; Xiaolan Su; Lei Dai; Yang Yang; Shuang Zhang; Dechao Yu; Yuquan Wei; Hongxin Deng
Journal:  J Cell Mol Med       Date:  2017-11-29       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.